Executive Summary
Azoth Analytics has released a research report titled "Incretin Based Drugs Market (2023 Edition)" which provides a complete analysis of the global Incretin Based Drugs industry in terms of market segmentation By Drug Type (Glucagon-like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors), By Route of Administration (Oral, Injectables) and By Indication (Diabetes, Obesity) for the historical period of 2018-2022, the estimated year of 2023 and the forecast period of 2024-2028.
The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast. The research also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market's evolution.
During the forecast period, 2024-2029, the Global Incretin Based Drugs market is expected to grow at a CAGR of 6.8%. The Global Incretin Based Drugs Market is expected to generate USD 64.28 billion by the end of 2029, up from USD 40.72 Billion in 2022.
Incretin-based drugs are the first-of-its-kind anti-hyperglycemic medications that have been developed by specifically targeting a recognized pathophysiological abnormality in type 2 diabetes. The global increase in the prevalence of type 2 diabetes has a significant impact on the demand for incretin-based drugs. The growing incidence of diabetes can be attributed to various factors, including sedentary lifestyles, poor dietary habits, and the ageing demographic.
In comparison to many other anti-hyperglycemic medications, incretin-based drugs offer some notable benefits, including the lack of an elevated risk of hypoglycemia or weight gain. The DPP4Is and GLP-1RAs exhibit unique efficacy and tolerability profiles, providing physicians with the opportunity to choose the most suitable medication for each patient, taking into account factors such as disease status (as indicated by HbA1c percentage), body weight, and patient preference for self-administered injectable drugs. The demand for Incretin-based drugs is expected to grow exponentially as the blockbuster drugs in the market become accessible in generic form and as upgraded formulations with reduced dosing frequency are introduced.
Scope of the Report
• The report analyses the Incretin Based Drugs Market by Value (USD Billion).
• The report presents the analysis of Incretin Based Drugs Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
• The report analyses the Incretin-Based Drugs Market by Drug Type (Glucagon-like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors).
• The report analyses the Incretin Based Drugs Market by Route of Administration (Oral, Injectables)
• The report analyses the Incretin-Based Drugs Market by Indication (Diabetes, Obesity).
• The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Drug Type, By Route of Administration and by Indications.
• Also, the major opportunities, trends, drivers, and challenges of the industry have been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk, AstraZeneca PLC, Merck & Co., Inc., Pfizer, Novartis AG, Takeda Pharmaceuticals, Bristol Myers Squibb, Structure Therapeutics.
1. Market Background
1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology
2. Strategic Recommendations
3. Global Incretin Based Drugs Market: Historic and Forecast (2018-2028)
3.1 Global Obesity Statistics 2022, in Millions
3.2 Pipeline Analysis of Incretin based drugs
3.3 Countries with the highest prevalence of diabetes worldwide in 2021
3.4 Estimated number of individuals with Diabetes Worldwide, in thousands (2000-2014E)
3.5 Global Incretin-Based Drugs Market: Dashboard
3.6 Global Incretin Based Drugs Market: Market Value Assessment, 2018-2028 (USD Billion)
3.7 Impact of COVID-19 on Global Incretin Based Drugs Market
3.8 Global Incretin-Based Drugs Market Segmentation: By Drug Type
3.8.1 Global Incretin-Based Drugs Market, By Drug Type Overview
3.8.2 Global Incretin Based Drugs Market Size, By Glucagon-like Peptide-1 Receptor Agonists, By Value, 2018H-2028F (USD Billion & CAGR)
3.8.3 Global Incretin Based Drugs Market Size, By Dipeptidyl Peptidase-4 Inhibitors, By Value, 2018H-2028F (USD Billion & CAGR)
3.9 Global Incretin-Based Drugs Market Segmentation: By Route of Administration
3.9.1 Global Incretin-Based Drugs Market, By Route of Administration Overview
3.9.2 Global Incretin-Based Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
3.9.3 Global Incretin-Based Drugs Market Size, By Injectables, By Value, 2018H-2028F (USD Billion & CAGR)
3.10 Global Incretin Based Drugs Market Segmentation: By Indication
3.10.1 Global Incretin Based Drugs Market, By Indication Overview
3.10.2 Global Incretin Based Drugs Market Size, By Diabetes By Value, 2018H-2028F (USD Billion & CAGR)
3.10.3 Global Incretin Based Drugs Market Size, By Obesity, By Value, 2018H-2028F (USD Billion & CAGR)
4. Global Incretin Based Drugs Market, Region Analysis
4.1 Regional Coverage of the Study
4.2 Regional Snapshot
5. Americas Incretin Based Drugs Market: Historic and Forecast (2018-2028)
5.1 Americas Incretin-Based Drugs Market: Snapshot
5.2 Americas Incretin-Based Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
5.3 Americas Incretin-Based Drugs Market: Key Factors
5.4 Americas Incretin-Based Drugs Market: Segment Analysis
5.5 Americas Incretin-Based Drugs Market Segmentation: By Drug Type
5.5.1 Americas Incretin-Based Drugs Market, By Drug Type Overview
5.5.2 Americas Incretin Based Drugs Market Size, By Glucagon-like Peptide-1 Receptor Agonists, By Value, 2018H-2028F (USD Billion & CAGR)
5.5.3 Americas Incretin Based Drugs Market Size, By Dipeptidyl Peptidase-4 Inhibitors, By Value, 2018H-2028F (USD Billion & CAGR)
5.6 Americas Incretin-Based Drugs Market Segmentation: By Route of Administration
5.6.1 Americas Incretin-Based Drugs Market, By Route of Administration Overview
5.6.2 Americas Incretin-Based Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
5.6.3 Americas Incretin-Based Drugs Market Size, By Injectables, By Value, 2018H-2028F (USD Billion & CAGR)
5.7 Americas Incretin-Based Drugs Market Segmentation: By Indication
5.7.1 Americas Incretin-Based Drugs Market, By Indication Overview
5.7.2 Americas Incretin-Based Drugs Market Size, By Diabetes, By Value, 2018H-2028F (USD Billion & CAGR)
5.7.3 Americas Incretin-Based Drugs Market Size, By Obesity, By Value, 2018H-2028F (USD Billion & CAGR)
5.8 Americas Incretin-Based Drugs Market Segmentation: By Country
5.8.1 United States Incretin-Based Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
5.8.1.1 United States Incretin-Based Drugs Market, By Drug Type
5.8.1.2 United States Incretin-Based Drugs Market, By Route of Administration
5.8.1.3 United States Incretin-Based Drugs Market, By Indication
5.8.2 Canada Incretin-Based Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
5.8.2.1 Canada Incretin-Based Drugs Market, By Drug Type
5.8.2.2 Canada Incretin-Based Drugs Market, By Route of Administration
5.8.2.3 Canada Incretin-Based Drugs Market, By Indication
5.8.3 Rest of Americas Incretin-Based Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
5.8.3.1 Rest of Americas Incretin-Based Drugs Market, By Drug Type
5.8.3.2 Rest of Americas Incretin-Based Drugs Market, By Route of Administration
5.8.3.3 Rest of Americas Incretin-Based Drugs Market, By Indication
6. Europe Incretin Based Drugs Market: Historic and Forecast (2018-2028)
6.1 Europe Incretin-Based Drugs Market: Snapshot
6.2 Europe Incretin-Based Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
6.3 Europe Incretin-Based Drugs Market: Key Factors
6.4 Europe Incretin-Based Drugs Market: Segment Analysis
6.5 Europe Incretin-Based Drugs Market Segmentation: By Drug Type
6.5.1 Europe Incretin-Based Drugs Market, By Drug Type Overview
6.5.2 Europe Incretin Based Drugs Market Size, By Glucagon-like Peptide-1 Receptor Agonists, By Value, 2018H-2028F (USD Billion & CAGR)
6.5.3 Europe Incretin Based Drugs Market Size, By Dipeptidyl Peptidase-4 Inhibitors, By Value, 2018H-2028F (USD Billion & CAGR)
6.6 Europe Incretin-Based Drugs Market Segmentation: By Route of Administration
6.6.1 Europe Incretin-Based Drugs Market, By Route of Administration Overview
6.6.2 Europe Incretin-Based Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
6.6.3 Europe Incretin-Based Drugs Market Size, By Injectables, By Value, 2018H-2028F (USD Billion & CAGR)
6.7 Europe Incretin-Based Drugs Market Segmentation: By Indication
6.7.1 Europe Incretin-Based Drugs Market, By Indication Overview
6.7.2 Europe Incretin-Based Drugs Market Size, By Diabetes, By Value, 2018H-2028F (USD Billion & CAGR)
6.7.3 Europe Incretin-Based Drugs Market Size, By Obesity, By Value, 2018H-2028F (USD Billion & CAGR)
6.8 Europe Incretin-Based Drugs Market Segmentation: By Country
6.8.1 Germany Incretin-Based Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
6.8.1.1 Germany Incretin-Based Drugs Market, By Drug Type
6.8.1.2 Germany Incretin Based Drugs Market, By Route of Administration
6.8.1.3 Germany Incretin Based Drugs Market, By Indication
6.8.2 United Kingdom Incretin Based Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
6.8.2.1 United Kingdom Incretin Based Drugs Market, By Drug Type
6.8.2.2 United Kingdom Incretin Based Drugs Market, By Route of Administration
6.8.2.3 United Kingdom Incretin Based Drugs Market, By Indication
6.8.3 France Incretin Based Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
6.8.3.1 France Incretin Based Drugs Market, By Drug Type
6.8.3.2 France Incretin Based Drugs Market, By Route of Administration
6.8.3.3 France Incretin Based Drugs Market, By Indication
6.8.4 Italy Incretin Based Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
6.8.4.1 Italy Incretin Based Drugs Market, By Drug Type
6.8.4.2 Italy Incretin Based Drugs Market, By Route of Administration
6.8.4.3 Italy Incretin Based Drugs Market, By Indication
6.8.5 Spain Incretin Based Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
6.8.5.1 Spain Incretin Based Drugs Market, By Drug Type
6.8.5.2 Spain Incretin Based Drugs Market, By Route of Administration
6.8.5.3 Spain Incretin Based Drugs Market, By Indication
6.8.6 Rest of Europe Incretin-Based Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
6.8.6.1 Rest of Europe Incretin-Based Drugs Market, By Drug Type
6.8.6.2 Rest of Europe Incretin-Based Drugs Market, By Route of Administration
6.8.6.3 Rest of Europe Incretin-Based Drugs Market, By Indication
7. Asia-Pacific Incretin Based Drugs Market: Historic and Forecast (2018-2028)
7.1 Asia-Pacific Incretin Based Drugs Market: Snapshot
7.2 Asia-Pacific Incretin Based Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
7.3 Asia-Pacific Incretin Based Drugs Market: Key Factors
7.4 Asia-Pacific Incretin Based Drugs Market: Segment Analysis
7.5 Asia-Pacific Incretin Based Drugs Market Segmentation: By Drug Type
7.5.1 Asia-Pacific Incretin Based Drugs Market, By Drug Type Overview
7.5.2 Asia-Pacific Incretin Based Drugs Market Size, By Glucagon-like Peptide-1 Receptor Agonists, By Value, 2018H-2028F (USD Billion & CAGR)
7.5.3 Asia-Pacific Incretin Based Drugs Market Size, By Dipeptidyl Peptidase-4 Inhibitors, By Value, 2018H-2028F (USD Billion & CAGR)
7.6 Asia-Pacific Incretin Based Drugs Market Segmentation: By Route of Administration
7.6.1 Asia-Pacific Incretin Based Drugs Market, By Route of Administration Overview
7.6.2 Asia-Pacific Incretin Based Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
7.6.3 Asia-Pacific Incretin Based Drugs Market Size, By Injectables, By Value, 2018H-2028F (USD Billion & CAGR)
7.7 Asia-Pacific Incretin Based Drugs Market Segmentation: By Indication
7.7.1 Asia-Pacific Incretin Based Drugs Market, By Indication Overview
7.7.2 Asia-Pacific Incretin Based Drugs Market Size, By Diabetes, By Value, 2018H-2028F (USD Billion & CAGR)
7.7.3 Asia-Pacific Incretin Based Drugs Market Size, By Obesity, By Value, 2018H-2028F (USD Billion & CAGR)
7.8 Asia-Pacific Incretin Based Drugs Market Segmentation: By Country
7.8.1 China Incretin Based Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
7.8.1.1 China Incretin Based Drugs Market, By Drug Type
7.8.1.2 China Incretin Based Drugs Market, By Route of Administration
7.8.1.3 China Incretin Based Drugs Market, By Indication
7.8.2 Japan Incretin Based Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
7.8.1.1 Japan Incretin Based Drugs Market, By Drug Type
7.8.1.2 Japan Incretin Based Drugs Market, By Route of Administration
7.8.1.3 Japan Incretin Based Drugs Market, By Indication
7.8.3 India Incretin Based Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
7.8.3.1 India Incretin Based Drugs Market, By Drug Type
7.8.3.2 India Incretin Based Drugs Market, By Route of Administration
7.8.3.3 India Incretin Based Drugs Market, By Indication
7.8.5 Rest of Asia-Pacific Incretin Based Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
7.8.5.1 Rest of Asia-Pacific Incretin Based Drugs Market, By Drug Type
7.8.5.2 Rest of Asia-Pacific Incretin Based Drugs Market, By Route of Administration
7.8.5.3 Rest of Asia-Pacific Incretin Based Drugs Market, By Indication
8. Middle-East & Africa Incretin Based Drugs Market: Historic and Forecast (2018-2028)
8.1 Middle-East & Africa Incretin Based Drugs Market: Snapshot
8.2 Middle-East & Africa Incretin Based Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
8.3 Middle-East & Africa Incretin Based Drugs Market: Key Factors
8.4 Middle-East & Africa Incretin Based Drugs Market: Segment Analysis
8.5 Middle-East & Africa Incretin Based Drugs Market Segmentation: By Drug Type
8.5.1 Middle-East & Africa Incretin Based Drugs Market, By Drug Type Overview
8.5.2 Middle-East & Africa Incretin Based Drugs Market Size, By Glucagon-like Peptide-1 Receptor Agonists, By Value, 2018H-2028F (USD Billion & CAGR)
8.5.3 Middle-East & Africa Incretin Based Drugs Market Size, By Dipeptidyl Peptidase-4 Inhibitors, By Value, 2018H-2028F (USD Billion & CAGR)
8.6 Middle-East & Africa Incretin Based Drugs Market Segmentation: By Route of Administration
8.6.1 Middle-East & Africa Incretin Based Drugs Market, By Route of Administration Overview
8.6.2 Middle-East & Africa Incretin Based Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
8.6.3 Middle-East & Africa Incretin Based Drugs Market Size, By Injectables, By Value, 2018H-2028F (USD Billion & CAGR)
8.7 Middle-East & Africa Incretin Based Drugs Market Segmentation: By Indication
8.7.1 Middle-East & Africa Incretin Based Drugs Market, By Indication: Overview
8.7.2 Middle-East & Africa Incretin Based Drugs Market Size, By Diabetes, By Value, 2018H-2028F (USD Billion & CAGR)
8.7.3 Middle-East & Africa Incretin Based Drugs Market Size, By Obesity, By Value, 2018H-2028F (USD Billion & CAGR)
9. Market Dynamics
9.1 Impact Assessment of Market Dynamics on Global Incretin-Based Drugs Market
9.2 Drivers
9.3 Restraints
9.4 Trends
10. Porter's Five Forces Analysis
10.1 Porter's Five Forces Model
11. Competitive Positioning
11.1 Companies' Product Positioning
11.2 Market Position Matrix
11.3 Market Share Analysis of Incretin-Based Drugs Market
11.4 Company Profiles
11.4.1 Eli Lilly and Company
11.4.2 Boehringer Ingelheim
11.4.3 Novo Nordisk
11.4.4 AstraZeneca PLC
11.4.5 Merck & Co., Inc.
11.4.6 Pfizer
11.4.7 Novartis AG
11.4.8 Takeda Pharmaceuticals
11.4.9 Bristol Myers Squibb
11.4.10 Structure Therapeutics
| Price : US$ 3500 |
Date : Nov 2024 |
| Category : Services |
Pages : 129 |
Request Sample 
Request Discount 
Inquire Before Buy
